Company Description
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.
It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems.
In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx’s knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions.
It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors.
The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018.
Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
| Country | United States |
| Founded | 2014 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 3,771 |
| CEO | Michael Greiner |
Contact Details
Address: 5405 Windward Parkway, Suite 100 South Alpharetta, Georgia 30004 United States | |
| Phone | 844 428 2667 |
| Website | avanos.com |
Stock Details
| Ticker Symbol | AVNS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001606498 |
| CUSIP Number | 05350V106 |
| ISIN Number | US05350V1061 |
| Employer ID | 46-4987888 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Joseph F. Woody | Chief Executive Officer and Director |
| Michael C. Greiner | Senior Vice President, Chief Financial Officer and Chief Transformation Officer |
| Mojirade James | Senior Vice President, General Counsel and Corporate Secretary |
| Kerr W. Holbrook | Senior Vice President and Chief Commercial Officer |
| John Joseph Hurley | Principal Accounting Officer and Controller |
| David Crawford | Vice President of FP&A and Investor Relations and Treasurer |
| Michelle Scharfenberg | Senior Vice President and Chief Ethics and Compliance Officer |
| Scott Galovan | Vice President of Strategy and Corporate Development |
| John W. Cato | Vice President of Human Resources |
| Lee Burnes | Senior Vice President of Global Research & Development, Clinical and Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 4, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 10-Q | Quarterly Report |
| Jul 31, 2024 | 8-K | Current Report |
| Jul 3, 2024 | 3 | Initial statement of beneficial ownership of securities |
| Jul 1, 2024 | 8-K | Current Report |
| May 28, 2024 | SD | Form - SD |
| May 13, 2024 | 8-K | Current Report |
| May 2, 2024 | 10-Q | Quarterly Report |